Increasing Ethnic Minority Participation in Substance Abuse Clinical Trials: Lessons Learned in the National Institute on Drug Abuse's Clinical Trials Network

被引:44
|
作者
Burlew, Kathleen [1 ]
Larios, Sandra [2 ]
Suarez-Morales, Lourdes [3 ]
Holmes, Beverly [4 ]
Venner, Kamilla [5 ]
Chavez, Roberta [5 ]
机构
[1] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA
[2] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA
[3] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Coral Gables, FL 33124 USA
[4] Lexington Richland Alcohol & Drug Abuse Council, So Consortium Node, Columbia, SC USA
[5] Univ New Mexico, Ctr Alcoholism Subst Abuse & Addict, Albuquerque, NM 87131 USA
关键词
recruitment; retention; ethnic minorities; clinical trials; research participation; MENTAL-HEALTH-SERVICES; MOTIVATIONAL ENHANCEMENT THERAPY; AFRICAN-AMERICAN; HISPANIC ADOLESCENTS; OROS-METHYLPHENIDATE; CANCER PREVENTION; OLDER MINORITIES; RECRUITMENT; COMMUNITY; INTERVENTION;
D O I
10.1037/a0025668
中图分类号
C95 [民族学、文化人类学];
学科分类号
0304 ; 030401 ;
摘要
Underrepresentation in clinical trials limits the extent to which ethnic minorities benefit from advances in substance abuse treatment. The objective of this article is to share the knowledge gained within the Clinical Trials Network (CTN) of the National Institute on Drug Abuse and other research on recruiting and retaining ethnic minorities into substance abuse clinical trials. The article includes a discussion of two broad areas for improving inclusion- community involvement and cultural adaptation. CTN case studies are included to illustrate three promising strategies for improving ethnic minority inclusion: respondent-driven sampling, community-based participatory research, and the cultural adaptation of the recruitment and retention procedures. The article concludes with two sections describing a number of methodological concerns in the current research base and our proposed research agenda for improving ethnic minority inclusion that builds on the CTN experience.
引用
收藏
页码:345 / 356
页数:12
相关论文
共 46 条
  • [31] Why providers participate in clinical trials: Considering the National Cancer Institute's Community Clinical Oncology Program
    McAlearney, Ann Scheck
    Song, Paula H.
    Reiter, Kristin L.
    CONTEMPORARY CLINICAL TRIALS, 2012, 33 (06) : 1143 - 1149
  • [32] Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Alzheimer's Disease: Future Directions
    Carlsson, Cynthia M.
    JOURNAL OF ALZHEIMERS DISEASE, 2008, 15 (02) : 327 - 338
  • [33] The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
    Chakraborty, Chiranjib
    Sharma, Ashish Ranjan
    Bhattacharya, Manojit
    Agoramoorthy, Govindasamy
    Lee, Sang-Soo
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [34] The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials
    Cummings, Jeffrey
    ALZHEIMERS & DEMENTIA, 2019, 15 (01) : 172 - 178
  • [35] Experiences of families with a child, adolescent, or young adult with neurofibromatosis type 1 and plexiform neurofibroma evaluated for clinical trials participation at the National Cancer Institute
    Martin, Staci
    Gillespie, Andrea
    Wolters, Pamela L.
    Widemann, Brigitte C.
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 (01) : 10 - 15
  • [36] Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future
    Cummings, Jeffrey
    Ritter, Aaron
    Zhong, Kate
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 : S3 - S22
  • [37] Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”
    Matisyahu Shulman
    Roger Weiss
    John Rotrosen
    Patricia Novo
    Elizabeth Costello
    Edward V. Nunes
    Addiction Science & Clinical Practice, 16
  • [38] Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials
    Cudkowicz, Merit
    Chase, Marianne K.
    Coffey, Christopher S.
    Ecklund, Dixie J.
    Thornell, Brenda J.
    Lungu, Codrin
    Mahoney, Katy
    Gutmann, Laurie
    Shefner, Jeremy M.
    Staley, Kevin J.
    Bosch, Michael
    Foster, Eric
    Long, Jeffrey D.
    Bayman, Emine O.
    Torner, James
    Yankey, Jon
    Peters, Richard
    Huff, Trevis
    Conwit, Robin A.
    JAMA NEUROLOGY, 2020, 77 (06) : 755 - 763
  • [39] Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)"
    Shulman, Matisyahu
    Weiss, Roger
    Rotrosen, John
    Novo, Patricia
    Costello, Elizabeth
    Nunes, Edward V.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2021, 16 (01)
  • [40] Designing clinical trials to address the needs of childhood and adult asthma: The National Heart, Lung, and Blood Institute's AsthmaNet
    Sutherland, E. Rand
    Busse, William W.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (01) : 34 - +